The European Diabetes Study Center has gathered a team of renowned scientific and medical experts, pioneers in their field of expertise, to fund a biotech company, ILONOV, focused on developing a novel class of therapeutics using the therapeutic potential of our muscle-derived biologic.
We aim at satisfying unmet medical needs in Type 1 Diabetes therapy by bringing to the market a first-in-class treatment for curing and preventing T1D and using our discovery to open up a new field of therapeutics.
Company Details
- Employees
- 5
- Founded
- -
- Address
- Boulevard René Leriche, Strasbourg,grand Est 67200,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Diabète, Recherche, Prévention, Traitement, Innovation, Médicament naturel, Muscle, Biotechnologie, Expertise, Diabetes, Health, Research.
- HQ
- Strasbourg, Grand Est
Ilonov Questions
Ilonov's LinkedIn profile is https://fr.linkedin.com/company/ilonov
Ilonov has
5 employees.
View email and phone details for 5
employees at Ilonov.
Ilonov's industry is
Biotechnology Research
Ilonov's top competitors are
Hocoia,
Selmod,
Baselaunch,
Biovalley France,
Domain Therapeutics,
T-Oncology Ag,
Biper Therapeutics,
Superbranche,
Continuum Plus Santé,
Netri.
Ilonov's categories are Biotechnology Research
Ilonov's founding year is 2020
